Olema Pharmaceuticals Inc's Customers Performance

Name: Olema Pharmaceuticals Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

OLMA

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


OLMA's Source of Revenues		• List of OLMA Customers

for the same period Olema Pharmaceuticals Inc

• List of OLMA Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Olema Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

The company has not established a commercial organization or distribution capabilities due to its development stage. It plans to build a commercial infrastructure to support sales of approved products. The company intends to evaluate partnerships to enhance development and commercialization capabilities for palazestrant and OP-3136. It also plans to commercialize its product candidates, if approved, in key markets either independently or with partners. The company does not own or operate manufacturing facilities and relies on third parties for manufacturing.

News about Olema Pharmaceuticals Inc Contracts

Novel Combinatory Therapeutics in ER+/HER2- Metastatic Breast Cancer: Promising Data on Palazestrant with CDK4/6 Inhibitors

: Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on developing targeted therapies for women s cancers, recently announced promising interim results from its ongoing Phase 1b/2 clinical studies. The studies involve the combination of palazestrant (OP-1250) with CDK4/6 inhibitors ribociclib and palbociclib in treating ER+/HER2- metastatic breast cancer. These findings have been presented at prominent oncology symposiums, including the 2024 ESMO Breast Cancer Annual Congress and the 2023 San Antonio Breast Cancer Symposium (SABCS). In an era where precision medicine is increasingly vital, Olema Oncology s latest research offers promising advancements for treating ER+/HER2- me...

Expanding Treatment Paradigms in Breast Cancer: An Exciting Development in Palazestrant and Ribociclib Combination Therapy

Breast cancer remains a significant global health concern, affecting millions of women around the world. Significant advances have been made in the field of oncology, and targeted therapies have emerged as powerful tools in the fight against this relentless disease. In this article, we explore the ground-breaking clinical data presented by Olema Oncology at the 2024 ESMO Breast Cancer Annual Congress. The company s novel approach, combining Palazestrant with Ribociclib, holds immense promise in revolutionizing treatment strategies for patients with breast cancer.Palazestrant - Unleashing the Potential:Palazestrant, developed by Olema Oncology, is a next-generation selective estrogen receptor degrader (SERD)....

Olema Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers

OLMA's Stock Performance relative to it's Customers

OLMA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Olema Pharmaceuticals Inc	1,082.14	0.00	-185.15	131
SUBTOTAL	0.00	0.00	0.00	-

Sources: Olema Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Olema Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Olema Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.